Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS67E in Acute Myeloid Leukemia (AML)
NCT02610062Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AGS67E in acute myeloid leukemia (AML) (5 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence and nature of adverse events up to 24 months. Started Mar 2016; status: terminated.
02
Drugs
AGS67E
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02610062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610062.